Ionis Pharmaceuticals
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell IONS and other ETFs, options, and stocks.About IONS
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T.
IONS Key Statistics
Stock Snapshot
As of today, Ionis Pharmaceuticals(IONS) shares are valued at $75.04. The company's market cap stands at 11.92B, with a P/E ratio of -42.98.
On 2025-11-08, Ionis Pharmaceuticals(IONS) stock moved within a range of $72.37 to $75.04. With shares now at $75.04, the stock is trading +3.7% above its intraday low and 0.0% below the session's peak.
Trading activity shows a volume of 2.17M, compared to an average daily volume of 2.25M.
The stock's 52-week range extends from a low of $23.95 to a high of $76.78.
The stock's 52-week range extends from a low of $23.95 to a high of $76.78.
IONS News
(RTTNews) - Ionis Pharmaceuticals Inc. (IONS) announced positive results from its pivotal Phase 3 CORE and CORE2 studies evaluating olezarsen in patients with s...
Ionis announced long-term data for Dawnzera for hereditary angioedema, or HAE, presented at the 2025 American College of Allergy, Asthma & Immunology, or ACAAI,...
Ionis Pharmaceuticals reported third-quarter 2025 results, with revenue rising to US$156.72 million and net loss narrowing to US$128.61 million compared to the...
Analyst ratings
73%
of 26 ratingsMore IONS News
Piper Sandler raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $77 from $70 and keeps an Overweight rating on the shares. The firm notes the co...
Ionis Pharmaceuticals (IONS) just delivered its third quarter results, revealing higher revenue and a smaller net loss than last year. The company also increase...